P0862 Elderly-onset inflammatory bowel disease (IBD) differs in disease characteristics and treatment exposures from adult-onset IBD

• DOI: 10.1093/ecco-jcc/jjae190.1036
• Publication Date: 2025-01-22T11:58:48Z
• Authors: M Granot; U Kopylov; N Nachum; A Krauthammer; B Tal; C M Abitbol; S Ben-Horin; B Weiss; Y Haberman
• Keywords: Adult-onset Still's disease

Abstract Background Elderly-onset inflammatory bowel disease (IBD) patients (age ≥60 at diagnosis) have unique characteristics and require special considerations. Using a real-life registry-based cohort, we compared treatment exposures between adult-onset elderly-onset IBD. Methods We analyzed data from comprehensive IBD registry, comparing demographics, characteristics, treatments (diagnosed 18≤ age <60 years) diagnosed during 2000-2022 with ≥12 months follow-up. Results included 3307 adult above the of 18 years. The median follow-up time was six 290 (9%) were In group, there higher fraction UC, 38.3% (111/290 IBD), only 31.4% (949/3017) UC cases in group (p=0.02). Similarly, within CD to presented more colonic L2 (21% vs. 12%, p<0.001) less ileocolonic L3 (14% 29%, p<0.001). Additionally, frequently penetrating B3 phenotype (7.4% 19%, perianal involvement (10% 20%, p<0.001), respectively. received significantly 5ASA (36% 17%, p<0.001 75% 63%, p=0.02 UC) considerably fewer biologics and/or JAK inhibitors (37% 56%, <0.001 20% 34%, UC). There no significant difference surgery rates two groups for UC. Kaplan-Meier curve Cox proportional hazard analyses showed 15-year (180 months) biologic-free survival diagnoses among (p<0.001, Figure 1 2 differences types first-line groups, receiving anti-TNF class medications (CD: 90% p<0.001, 63% 23%, Vedolizumab as biologic 46% 10%, UC: 68% 38%, Conclusion This real-world registry analysis reveals that is characterized by prevalence colonic-only CD, disease. Treatment strategies favor 5-ASA show reduced use, preferences vs anti-TNFs